Context

Fresenius Kabi agreed to acquire 100% of Ivenix, delivering on its "Expand MedTech" growth vector under its Vision 2026 strategy. The combination of Ivenix's leading hardware and software infusion platform with Fresenius Kabi's existing intravenous fluids and infusion device portfolio creates a comprehensive premium MedTech offering for the US market. Significant scale and growth synergies are expected from the transaction. The Ivenix Infusion System is expected to be neutral to Fresenius Kabi's Group cash earnings per share in 2025 and accretive from 2026 onwards.

Target

Ivenix is a privately held US-based medical technology company specialising in next-generation infusion therapy systems. The company has developed what is considered the technologically most advanced infusion system available, comprising a large volume pump (LVP) with administration sets, infusion management software tools, applications, and analytics designed to improve care delivery and operational efficiency. The Ivenix Infusion System sets a new standard in infusion safety, simplicity, and interoperability, centred around the patient and clinician experience, and is specifically designed to reduce infusion-related errors and lower the total cost of ownership for healthcare providers. The system received FDA approval and was successfully commercially launched in the United States in late 2021.